Incyte Corporation $INCY Stock: Illinois Municipal Retirement Fund Reduces Stake

Posted by Geri Gentry on Nov 11th, 2026

Illinois Municipal Retirement Fund decreased its holdings in shares of Incyte Corporation (NASDAQ:INCY – Free Report) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 247,227 shares of the biopharmaceutical company’s stock after selling 13,111 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Incyte were worth $30,001,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lido Advisors LLC raised its position in shares of Incyte by 1.2% during the 3rd quarter. Lido Advisors LLC now owns 18,556 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 229 shares in the last quarter. Keybank National Association OH boosted its holdings in Incyte by 6.9% during the 3rd quarter. Keybank National Association OH now owns 2,626 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 169 shares during the period. New York Life Investment Management LLC increased its stake in Incyte by 1.3% in the 3rd quarter. New York Life Investment Management LLC now owns 23,656 shares of the biopharmaceutical company’s stock worth $2,871,000 after purchasing an additional 297 shares during the period. AlphaCore Capital LLC purchased a new position in Incyte in the 3rd quarter worth approximately $249,000. Finally, Retirement Systems of Alabama increased its stake in Incyte by 1.3% in the 3rd quarter. Retirement Systems of Alabama now owns 35,706 shares of the biopharmaceutical company’s stock worth $4,333,000 after purchasing an additional 452 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Benchmark reissued a “buy” rating on shares of Incyte in a research note on Tuesday, October 13th. Mizuho increased their price target on shares of Incyte from $121.00 to $137.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Guggenheim increased their price target on shares of Incyte from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wells Fargo & Company cut their price target on shares of Incyte from $128.00 to $127.00 and set an “equal weight” rating on the stock in a report on Friday, October 30th. Finally, Leerink Partners decreased their price objective on shares of Incyte from $154.00 to $150.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Eleven research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $132.86.

Read Our Latest Analysis on Incyte

Incyte Stock Down 1.3%

NASDAQ:INCY opened at $120.30 on Wednesday. The stock has a market cap of $24.52 billion, a P/E ratio of 57.49, a price-to-earnings-growth ratio of 4.44 and a beta of 0.78. The firm’s fifty day simple moving average is $119.51 and its 200 day simple moving average is $108.67. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The business had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the previous year, the firm earned $2.26 EPS. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. On average, analysts expect that Incyte Corporation will post 2.24 EPS for the current fiscal year.

Insider Activity

In other news, insider Pablo Cagnoni sold 2,642 shares of Incyte stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total transaction of $297,779.82. Following the sale, the insider owned 183,200 shares of the company’s stock, valued at approximately $20,648,472. The trade was a 1.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the business’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider owned 21,126 shares in the company, valued at $2,513,148.96. This represents a 2.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 254,246 shares of company stock valued at $30,162,968. Corporate insiders own 16.20% of the company’s stock.

Incyte Profile

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.